nevadensin has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, JX; Shen, ZM; Sun, YF; Xu, B; Yang, JL | 1 |
| Liu, X; Meng, Z; Sun, Z; Wang, D; Yang, A; Zhang, P; Zhang, X | 1 |
2 other study(ies) available for nevadensin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
[Cultured human hepatoma cells (BEL-7404) for anticancer drugs screening].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cells, Cultured; Colony-Forming Units Assay; Drug Evaluation, Preclinical; Flavones; Flavonoids; Harringtonines; Homoharringtonine; Humans; Liver Neoplasms; Tumor Stem Cell Assay | 1985 |
Lysionotin induces apoptosis of hepatocellular carcinoma cells via caspase-3 mediated mitochondrial pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Flavones; Humans; Liver Neoplasms; Male; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mitochondria; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |